Real-World Benefits of Mepolizumab in Patients With Overlapping Allergic and Eosinophilic Endophenotypes: Post Hoc Analysis of REALITI-A by Omalizumab Eligibility

Up to 73% of patients with severe asthma have overlapping allergic and eosinophilic endophenotypes and are eligible for treatment with anti-eosinophilic (e.g., mepolizumab) or anti-IgE (omalizumab) biologics. We assessed mepolizumab real-world effectiveness in patients with severe asthma and overlapping endophenotypes based on omalizumab treatment eligibility.